• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Atossa Therapeutics Inc.

    3/26/25 4:05:50 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATOS alert in real time by email
    S-8 1 atos-20250325.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 26, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

    ATOSSA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

    Delaware
    (State or Other Jurisdiction of Incorporation or Organization)

    26-4753208

    (I.R.S. Employer Identification No.)

    Atossa Therapeutics, Inc.

    10202 5th Avenue NE, Suite 200

    Seattle, Washington 98125

    (Address of Principal Executive Offices, Zip Code)

    Atossa Therapeutics, Inc. 2020 Stock Incentive Plan, as amended


    (Full title of the plan)

    Heather Rees

    Chief Financial Officer and Secretary

    10202 5th Avenue NE, Suite 200

    Seattle, Washington 98125

    (206) 588-0256

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copy to:

    Sean Feller

    Gibson, Dunn & Crutcher LLP

    2029 Century Park East, Suite 4000

    Los Angeles, CA 90067-3026

    (310) 552-8500

    ______________________________________________

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☑

    Smaller reporting company

    ☑

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


    INTRODUCTION

    This Registration Statement on Form S-8 is being filed by Atossa Therapeutics, Inc., a Delaware corporation (the “Company” or the “Registrant”), to register an additional 12,000,000 shares of its common stock, par value $0.18 per share (the “Common Stock”) issuable to eligible individuals under the Atossa Therapeutics, Inc. 2020 Stock Incentive Plan, as amended (the “2020 Plan”).

    The information contained in the Registrant’s Registration Statement on Form S-8 filed with the Securities Exchange Commission (the “Commission”) on March 31, 2021 (Registration No. 333-254905), together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E on Form S-8, and the shares of Common Stock registered hereunder are in addition to the shares of Common Stock registered on such registration statement with respect to the 2020 Plan.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    EXHIBIT INDEX

    Incorporated by Reference Herein

    Exhibit No.

    Description

    Form

    Date

    4.1

    Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc.

    Registration Statement on Form S-1/A, as Exhibit 3.2

    June 11, 2012

    4.2

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc.

    Current Report on Form 8-K, as Exhibit 4.1

    August 26, 2016

    4.3

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc.

    Current Report on Form 8-K, as Exhibit 4.1

    April 23, 2018

    4.4

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc.

    Current Report on Form 8-K, as Exhibit 3.1

    January 7, 2020

    4.5

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Atossa Therapeutics, Inc.

    Current Report on Form 8-K, as Exhibit 3.1

    July 2, 2024

    4.6

    Amended and Restated Bylaws of Atossa Therapeutics, Inc.

    Current Report on Form 8-K, as Exhibit 3.2

    April 26, 2023

    5.1*

    Opinion of Gibson, Dunn & Crutcher LLP

    Filed herewith

    23.1*

    Consent of Gibson, Dunn & Crutcher LLP

    Included in Exhibit 5.1

    23.2*

    Consent of Ernst & Young LLP

    Filed herewith

    24.1*

    Power of Attorney

     

    99.1

    Atossa Therapeutics, Inc. 2020 Stock Incentive Plan, as amended June 27, 2024

    Current Report on Form 8-K, as Exhibit 10.1

     

    July 2, 2024

    107*

    Filing Fee Table

    Filed herewith

    *Filed herewith.

    SIGNATURES


    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on this March 26, 2025.

    Atossa Therapeutics, Inc.

    By:

    /s/ Heather Rees

    Name:

    Heather Rees

    Title:

    Chief Financial Officer and Secretary

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven C. Quay, M.D., Ph.D. and Heather Rees, and each of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement and filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

    Office(s)

    Date

    /s/ Steven C. Quay

    Chairman, President and Chief Executive Officer

    March 26, 2025

    Steven C. Quay, M.D., Ph.D.

    (Principal Executive Officer)

    /s/ Heather Rees

    Chief Financial Officer and Secretary

    March 26, 2025

    Heather Rees

     

    /s/ Richard I. Steinhart

    Director

    March 26, 2025

    Richard I. Steinhart

    /s/ Shu-Chih Chen

    Director

    March 26, 2025

    Shu-Chih Chen, Ph.D.

    /s/ Jonathan Finn

    Director

    March 26, 2025

    Jonathan Finn

    /s/ Stephen J. Galli

    Director

    March 26, 2025

    Stephen J. Galli, M.D.

    /s/ H. Lawrence Remmel

    Director

    March 26, 2025

    H. Lawrence Remmel

    /s/ Tessa Cigler

    Director

    March 26, 2025

    Tessa Cigler, M.D., M.P.H.



    Get the next $ATOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

      Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profile SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today reported full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 TRIAL evaluating low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive (ER+), HER2‑negative breast cancer. ATOS) i

      5/14/25 8:15:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

      Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication  Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments.

      5/13/25 8:00:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

      SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,281,056) directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeutic methods of using those oral formulations. The newly granted patent includes 58 claims covering (Z)-endoxifen formulations, including various levels of purity and stability as well as methods of using those formulations. This patent provides additio

      4/30/25 8:45:06 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      3/28/25 4:00:03 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Galli Stephen J

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      7/1/24 4:00:06 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Steinhart Richard I

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      7/1/24 4:00:11 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

      SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

      11/12/24 1:32:30 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

      SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

      11/4/24 11:27:58 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atossa Therapeutics Inc. (Amendment)

      SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

      2/9/23 11:07:47 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      3/28/25 4:00:03 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Finn Jonathan bought $44,250 worth of shares (25,000 units at $1.77) (SEC Form 4)

      4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

      4/11/24 4:05:09 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Financials

    Live finance-specific insights

    See more
    • Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

      Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication  Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments.

      5/13/25 8:00:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

      Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre

      3/25/25 8:00:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

      SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024. The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-

      3/20/25 9:13:10 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    Leadership Updates

    Live Leadership Updates

    See more
    • Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

      Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical trial conducted in partnership with Quantum Leap Healthcare Collaborativeä evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO)Received a new patent (U.S. Patent No. 12

      11/12/24 8:30:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

      SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership roles in global clinical programs across immunology, oncology, and metabolic disease. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer. Dr. Lopez most recently served as Vice President of Clinical Development at Landos Biopharma, where she oversaw global clinical strategies, trial

      11/5/24 8:30:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

      SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. "We are excited to welcome Michael t

      8/20/24 8:30:00 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATOS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Atossa Therapeutics Inc.

      10-Q - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

      5/13/25 8:15:19 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

      5/13/25 8:05:08 AM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atossa Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

      4/7/25 4:05:13 PM ET
      $ATOS
      Biotechnology: Pharmaceutical Preparations
      Health Care